IRIS
DE LUCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.941
EU - Europa 14.741
AS - Asia 2.416
SA - Sud America 41
OC - Oceania 33
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 16
Totale 36.209
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.882
GB - Regno Unito 5.810
IE - Irlanda 2.505
IT - Italia 1.918
UA - Ucraina 1.889
CN - Cina 1.781
SE - Svezia 868
FR - Francia 855
DE - Germania 320
VN - Vietnam 238
FI - Finlandia 198
SG - Singapore 142
RU - Federazione Russa 106
ES - Italia 82
TR - Turchia 61
BE - Belgio 53
IN - India 53
CA - Canada 42
IR - Iran 29
AU - Australia 27
HK - Hong Kong 25
AT - Austria 23
BR - Brasile 18
EU - Europa 16
NL - Olanda 16
CZ - Repubblica Ceca 13
GR - Grecia 13
PL - Polonia 13
CO - Colombia 11
JP - Giappone 11
ID - Indonesia 9
PH - Filippine 8
PK - Pakistan 8
SK - Slovacchia (Repubblica Slovacca) 8
LU - Lussemburgo 7
BD - Bangladesh 6
IL - Israele 6
MX - Messico 6
CH - Svizzera 5
HU - Ungheria 5
KR - Corea 5
NZ - Nuova Zelanda 5
AR - Argentina 4
BG - Bulgaria 4
LB - Libano 4
MN - Mongolia 4
NO - Norvegia 4
PA - Panama 4
TH - Thailandia 4
BW - Botswana 3
CL - Cile 3
EE - Estonia 3
EG - Egitto 3
ET - Etiopia 3
IM - Isola di Man 3
JM - Giamaica 3
NG - Nigeria 3
PE - Perù 3
PT - Portogallo 3
RO - Romania 3
SA - Arabia Saudita 3
TW - Taiwan 3
BY - Bielorussia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GH - Ghana 2
IQ - Iraq 2
KZ - Kazakistan 2
LK - Sri Lanka 2
RS - Serbia 2
SN - Senegal 2
UG - Uganda 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
MY - Malesia 1
NC - Nuova Caledonia 1
SI - Slovenia 1
SV - El Salvador 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 36.209
Salva come PNG Salva come JPEG
Città #
Southend 5.392
Fairfield 2.996
Dublin 2.489
Chandler 1.842
Jacksonville 1.563
Ashburn 1.522
Woodbridge 1.506
Seattle 1.183
Wilmington 1.172
Cambridge 1.050
Houston 1.028
Ann Arbor 659
Menlo Park 516
Princeton 504
Nanjing 469
Siena 425
Boardman 277
Beijing 273
Dong Ket 229
San Diego 164
Nanchang 147
Shenyang 135
Helsinki 117
Dearborn 115
Rome 113
Milan 112
New York 105
Moscow 91
Tianjin 91
Singapore 89
Hebei 88
Changsha 82
San Mateo 78
Jiaxing 68
Málaga 65
London 60
Kunming 51
Shanghai 50
Brussels 48
Bologna 47
Jinan 47
Norwalk 47
Ningbo 46
Zhengzhou 46
Izmir 44
Florence 40
Taizhou 33
Lancaster 31
San Francisco 31
Falls Church 30
Turin 30
Guangzhou 29
Toronto 29
Hefei 24
Redwood City 22
Naples 21
Vienna 21
Düsseldorf 20
Los Angeles 20
Phoenix 20
Hangzhou 19
Chiswick 17
Genoa 17
Catania 16
Melbourne 16
Padova 16
Lanzhou 15
Tappahannock 15
Kilburn 14
Washington 14
Fremont 13
Hounslow 13
Karaj 13
Lappeenranta 13
Changchun 11
New Orleans 11
Frankfurt am Main 10
Horsham 10
Mestre 10
Coventry 9
Fuzhou 9
Groningen 9
Kowloon 9
Madrid 9
Perugia 9
Falkenstein 8
Nottingham 8
Bari 7
Bratislava 7
Brno 7
Central 7
Chicago 7
Islington 7
Leawood 7
Parma 7
Spezzano Della Sila 7
Stockholm 7
Tokyo 7
Atlanta 6
Berlin 6
Totale 28.064
Salva come PNG Salva come JPEG
Nome #
Utilizzo di dalbavancina nella terapia delle infezioni osteoarticolari 668
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: Implications for the activity of next-line regimens from a longitudinal study in Mozambique 540
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 451
Meningoencefalite da Listeria e sindrome di Miller-Fisher: un’inusuale associazione 393
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study 347
Staphylococcus aureus vaccine preclinical and clinical development: current state of the art 339
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 331
ERITEMA NODOSO RECIDIVANTE E PERSISTENTE REPLICA DI EPSTEIN-BARR VIRUS 269
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 254
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 253
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 219
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 210
UTILIZZO DI MILTEFOSINA IN PAZIENTE CON LEISHMANIOSI MUCOSA ED INFEZIONE DA HIV 205
Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes 198
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 194
Non-granulomatous cerebellar infection by Acanthamoeba spp. in an immunocompetent host 191
Clinical and MRI improvement in a case of progressive multifocal leukoencephalopathy 181
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 180
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 179
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 178
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 177
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 176
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 174
Evolution of macrolide resistance in streptococcus pyogenes over 14 years in an area of central Italy 174
Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature 172
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 171
Case Report: Persistent strongyloidiasis complicated by recurrent meningitis in an HTLV seropositive Peruvian migrant resettled in Italy 169
Sieroprevalenza di HEV in donatori di sangue e pazienti trapiantati di rene nella provincia di Siena. 169
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 168
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 165
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 164
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 164
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 164
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients 163
Nuovi approci diagnostici nelle infezioni pneumococciche: possibile ruolo della Real-time PCR e dei biomarcatori 161
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 161
Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy [Sieroprevalenza dell’infezione da virus dell’epatite E (HEV) in donatori di sangue e pazienti trapiantati di rene: Uno studio retrospettivo dal centro Italia] 158
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 158
Un caso di “insolita” spondilodiscite da Staphylococcus capitis 157
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 156
Prevalence of M75 Streptococcus Pyogenes strains harboring slaa gene in patients affected by pediatric obstructive sleep apnea syndrome in Central Italy 152
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 150
HCMV infection in renal transplant recipients: a retrospective cohort study 150
Un rarissimo caso di infestazione parassitaria cerebellare da Acanthamoeba spp. In soggetto immunocompetente: primo caso in Italia. 148
High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype 147
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 147
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 145
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 144
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 143
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 142
FIBRILLO-FLUTTER IN ASSENZA DI SEGNI DI MIOCARDITE IN CORSO DI INFEZIONE DA EBV 139
European guidelines on the clinical management of HIV-1 tropism testing 139
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. 138
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 138
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. 138
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 138
Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion 136
Gastroenteritis and Intractable Diarrhea in Newborns 136
A novel methodology for large-scale phylogeny partition 135
null 135
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 134
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load 134
Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings 133
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy 132
null 131
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 131
MIASI CAVITARIA A LOCALIZZAZIONE NASALE DA OESTRUS OVIS: UN CASO CLINICO 131
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 131
Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics 130
null 129
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 128
Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients 127
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 126
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 126
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 126
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 126
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 125
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 125
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 124
Risposta immunitaria a lungo termine dopo vaccinazione antipneumococcica con vaccino coniugato 13-valente o vaccino polisaccaridico 23-valente in adulti HIV positivi 123
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 123
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 122
Evoluzione ed efficace controllo di un vasto focolaio epidemico nosocomiale da Klebsiella pneumoniae produttrice di carbapenemasi in un’area Neurochirurgica: lezioni apprese. 121
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 120
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 120
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 119
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. 119
Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa 118
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 118
Local and global spatio-temporal dynamics of HIV-1 subtype F1 118
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe 117
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 116
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 116
Valutazione della risposta al test IGRA in pazienti pediatrici contatto di TBC o con sospetto clinico di infezione attiva 116
No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy 115
Treatment of HCV infection with the novel NS3/4A protease inhibitors 115
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 115
The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy 114
null 114
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 114
Totale 16.863
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.613
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.613
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209.592 1.110 418 697 1.538 609 686 991 1.244 808 757 216 518
2020/20216.029 221 875 203 576 464 654 329 937 330 625 256 559
2021/20223.750 257 499 148 289 141 171 179 190 215 444 362 855
2022/20235.940 383 322 606 924 697 1.313 80 480 647 145 180 163
2023/20243.831 205 126 296 152 153 888 1.249 133 27 128 164 310
2024/2025140 140 0 0 0 0 0 0 0 0 0 0 0
Totale 37.109